- The collaboration is underpinned by a shared commitment to
advancing medical science and improving patient care through joint
research, development, and innovation efforts
- One of the first areas of focus under this agreement will be
deepened collaborations in the field of preterm birth-associated
early onset respiratory disease.
PARMA, Italy, May 14, 2024
/PRNewswire/ -- Chiesi Group, a research-oriented international
biopharmaceutical group, proudly announces the signing of a
memorandum of understanding with Karolinska
Institutet, a medical university. The agreement solidifies a
commitment between the two organizations to collaborate on joint
efforts aimed at advancing therapeutic solutions for urgent health
challenges.
The landmark collaboration between Chiesi and Karolinska Institutet (KI), will accelerate
research and development initiatives for respiratory diseases, rare
diseases, diseases of prematurity, and other specialty care
indications.
Chiesi Group and KI will exchange ideas, expertise, and
resources to accelerate the translation of scientific discoveries
into tangible healthcare solutions. Their collaboration is
underpinned by a shared commitment to advancing medical science and
improving patient care through joint research, development, and
innovation efforts.
Fabrizio Conicella, Head of
Chiesi's Center for Open Innovation and Competence, said: "We
believe that this partnership with such a world-renowned academic
center of excellence will provide significant opportunities to not
only accelerate our pipeline but to explore and establish novel
innovative ways of working between academia and industry".
Mark Parry-Billings, Head of Drug
Development at Chiesi and Site Head of Chiesi's R&D operations
based in the Karolinska Science Park, stated, "We are delighted
to advance our work with KI through this collaborative agreement,
which will leverage past successes and form a platform for a close
and dynamic research and development partnership, in a series of
focused scientific disciplines, including for example in the field
of translational medicine."
Åsa Wheelock, Board member of the Chiesi-KI alliance and Head of
the Respiratory Medicine Unit, Department of Medicine Solna, at KI
declared, "We are thrilled to embark on this strategic
collaboration with Chiesi Group, a partnership that embodies our
shared commitment to advancing scientific research and improving
patient care. KI and Chiesi have a long and successful track record
of collaborations in the field of respiratory disease and
neonatology. This alliance provides an enhanced platform to expand
our collaborations beyond our ongoing joint efforts on sub-grouping
of patients in the asthma-COPD spectrum. As such, this
collaboration underscores Karolinska
Institutet's dedication to translating cutting-edge research
into tangible solutions that address the needs of patients
worldwide".
Through this partnership, Chiesi Group and KI are poised to
drive innovation, accelerate scientific discovery, and ultimately
improve patient outcomes in areas of high unmet need.
About Chiesi Group
Chiesi is research-oriented international biopharmaceutical
group that develops and markets innovative therapeutic solutions in
respiratory health, rare diseases, and specialty care. The
company's mission is to improve people's quality of life and act
responsibly towards both the community and the environment.
By changing its legal status to a Benefit Corporation in
Italy, the US, and France, Chiesi's commitment to create shared
value for society as a whole is legally binding and central to
company-wide decision-making. As a certified B Corp since 2019,
we're part of a global community of businesses that meet high
standards of social and environmental impact. The company aims to
reach Net-Zero greenhouse gases (GHG) emissions by 2035.
With over 85 years of experience, Chiesi is headquartered in
Parma (Italy), with 31 affiliates
worldwide, and counts more than 7,000 employees. The Group's
research and development centre in Parma works alongside 6 other
important R&D hubs in France,
the US, Canada, China, the UK, and Sweden.
For further information please visit www.chiesi.com
About Karolinska Institutet
(KI)
As one of the world's foremost medical universities, KI accounts
for the single largest share of all academic medical research
conducted in Sweden. KI also
offers the country's broadest range of education in medicine and
health sciences. The research spans the entire biomedical field –
from basic experimental research to clinical studies in
collaboration with the health care system.
View original
content:https://www.prnewswire.com/news-releases/chiesi-group-forges-alliance-with-karolinska-institutet-to-tackle-urgent-health-challenges-302144021.html
SOURCE Chiesi Group